Clinical Study on Safety of Cantharidin Sodium and Shenmai Injection Combined with Chemotherapy in Treating Patients with Breast Cancer Postoperatively

Objectives: To assess side effects on Cantharidin sodium and Shenmai injection combined with chemotherapyin treating patients with breast cancer postoperatively. Method: Patients with breast cancer receiving postoperativechemotherapy were retrospectively collected, and divided into four groups: group A with cantharidin sodiuminjection combined with chemotherapy; group B with Shenmai injection combined with chemotherapy; groupC with both cantharidin sodium and Shenmai injection combined with chemotherapy; while group D (controlgroup) received chemotherapy alone. All patients were administered docetaxel at a dose of 75 mg /m2 on day 1,epirubicin hydrochloride at a dose of 60 mg /m2 on day 1, and cyclophosphamide at a dose of 500 mg/m2 on day1 for 3 cycles (repeated at 21 day intervals). After ≥ three courses of treatment, quality of life and side effectswere evaluated. Results: There were a total of 78 patients in this study, and the incidence of leukopenia andgastrointestinal reactions in groups A and B were lower than those in the control group and lowest in group C(p<0.05). Conclusions: Thus cantharidin sodium and Shenmai injection combined with chemotherapy reduceside effects and deserve to be further investigated in randomized clinical control trials.